Physician profile
Hayley E Maislos
NPI 1225292527
$15,130.01
in general payments reported to CMS, 2019-2025
38 companies · $3,161 in 2025
The $3,161 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,193 · 2020: $511 · 2021: $1,252 · 2022: $2,656 · 2023: $2,838 · 2024: $2,518 · 2025: $3,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,516 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,516.29 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,738.27 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,622.07 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $1,244.15 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $1,183.32 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $1,181.50 | 2019-2025 | Trintellix |
| Abbvie INC. | $1,132.81 | 2021-2025 | |
| Lundbeck LLC | $1,005.57 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $973.11 | 2019-2025 | Ingrezza |
| Corium, LLC | $657.87 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $588.68 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $563.10 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $500.38 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $498.12 | 2019-2022 | |
| Tris Pharma INC | $256.07 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $210.99 | 2022-2024 | Qelbree, Qelbree |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $180.21 | 2019-2020 | |
| Axsome Therapeutics, INC. | $177.93 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $163.29 | 2025 | Cobenfy |
| Neos Therapeutics, LP | $158.32 | 2019-2025 | Adzenys Xr-Odt |
| Shire North American Group INC | $156.68 | 2019 | |
| Jazz Pharmaceuticals INC. | $113.94 | 2019-2021 | |
| Noven Therapeutics, LLC | $113.58 | 2021-2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $110.44 | 2023-2025 | Quviviq, Quviviq |
| Ironshore Pharmaceuticals INC. | $100.92 | 2020-2024 | Jornay Pm |
| Almatica Pharma LLC | $69.28 | 2021-2023 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $50.09 | 2019-2023 | Subvenite, Lamotrigine |
| Rhodes Pharmaceuticals L.P. | $47.09 | 2019 | |
| Indivior INC. | $46.43 | 2022 | |
| Validus Pharmaceuticals LLC | $42.53 | 2019-2022 | |
| Adlon Therapeutics L.P. | $41.73 | 2019 | |
| Eisai INC. | $40.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.63 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $32.17 | 2019 | |
| Mdd US Operations, LLC | $23.65 | 2019 | |
| Boston Scientific Corporation | $17.86 | 2025 | General - Dbs |
| Lilly USA, LLC | $17.49 | 2024 | Jardiance, Zepbound |
| Neuronetics, INC. | $17.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayley Maislos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.